Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fibrex Medical Inc.

www.fibrexmedical.com

Latest From Fibrex Medical Inc.

In Split, Ikaria Looks For Products, While New R&D Play Preps For IPO

In a partial buy-out by new private equity investor Madison Dearborn Partners, Ikaria is refocused on building out its critical care product portfolio, while a new R&D spin-out may take a route to the public markets. Existing investors have already done nicely through a series of dividends.

BioPharmaceutical Strategy

Ikaria plans $200 million IPO

Ikaria, a US-based biotherapeutic company, is hoping to raise $200 million through an IPO. It intends to list on Nasdaq.

Cardiovascular Companies

Start-Up Quarterly Statistics, Q3 2009

Highlights from the Q3 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $520 million, a 40% decrease from the previous quarter and a 45% drop from Q3 2008. Of the total money raised in the current quarter, 64% or $333 million went to the biopharma companies. Compared with Q2 2009, device fundraising decreased by 76% (from $465 million to $113 million) but diagnostics companies raised significantly more--going from $23 million to $74 million. In contrast to the previous quarter, which saw only one acquisition, in Q3 2009 there were four involving start-ups, all of which are focusing on neurological disorders. On the alliance front, three companies--Oscient, NovaMed, and Ikaria Holdings--signed two deals each this quarter.
BioPharmaceutical Medical Device

Ikaria acquires peptide compounds from Fibrex

Ikaria has acquired the global licence to Fibrex Medical's portfolio of investigational compounds, including the fibrin-derived peptides FX06, FX201 and FX107.

Cardiovascular Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • Fibrex Medical Inc.
  • Senior Management
  • Rainer Henning, PhD, CEO
    Peter Petzelbauer, MD, CSO
    Irina Staatz-Granzer, PhD, CBO
  • Contact Info
  • Fibrex Medical Inc.
    Phone: (43) 890 0617
    Gastgebgasse 5-13
    Vienna, A-1230
    Austria
Advertisement
Advertisement
UsernamePublicRestriction

Register